secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2026-09-28T21:07:31+00:00
Accession:  0001437749-26-031389
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

CervoMed says new 50 mg neflamapimod tablet plus FDA removal of exposure limit enables 100 mg BID dosing
--------------------------------------------------------------------------------

- New 50 mg tablet uses most stable crystalline form, addressing manufacturing variability of the 40 mg capsule in Phase 2b RewinD-LB; Phase 1 food-effect/drug-exposure study met primary objectives.
- 50 mg tablet vs prior 40 mg capsule: similar overall plasma exposure, ~20% lower Cmax and ~20% higher 12-hour trough, supporting twice-daily dosing.
- FDA removed neflamapimod's prior plasma exposure limit after a 39-week dog tox study set a NOAEL 3-fold higher than prior dog studies and >30x the active clinical exposure range.
- Plans 100 mg BID regimen; PK modeling projects ~33% higher trough levels than the 40 mg TID dose used in Phase 2a and the Phase 2b extension in DLB, cutting dosing to twice daily.
- CEO John J. Alam says the new tablet addresses the formulation issue from RewinD-LB and expects substantially higher trough concentrations, reducing clinical execution and CMC risk.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774926031389/0001437749-26-031389-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774926031389/crvo20260928_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-031389

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer